<DOC>
	<DOCNO>NCT01327014</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy XueZhiKang improve plasma lipid profile , compare placebo , outpatient hyperlipidemia .</brief_summary>
	<brief_title>Efficacy Safety Study Lipid-Lowering Effects XueZhiKang ( XZK ) Patients With Hyperlipidemia</brief_title>
	<detailed_description>This multi-center , double-blind , randomize , placebo-controlled , parallel group study conduct approximately 120 patient hyperlipidemia approximately 10 site US China . Patients satisfy entry criterion screen visit 4-week Therapeutic Lifestyle Changes ( TLC ) diet control period lipid-lowering medication discontinue . After 4-week diet control period , eligible patient randomize one three treatment group . The treatment period last 12-weeks . Patients blood sample collect 5 time point ( screen , baseline , Week 4 , Week 8 , Week 12 ) .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>1 . Patients diagnose hyperlipidemia define fasting level TC ≥ 240 mg/dl LDLC ≥ 160 mg/dl &lt; 190 mg/dl TG &lt; 400 mg/dl . 2 . Patients 10year coronary heart disease risk Framingham Point Score &lt; 10 % . 3 . Male female patient , race , least 18 year age . 4 . Female patient must postmenopausal defined menstruation least 12 month , surgically sterilize least three month prior begin study , negative pregnancy test agree avoid pregnancy study one month end study use two reliable method contraception . 5 . Patients must inform aspect study sign informed consent form studyrelated activity . 6 . Patients must willing follow TLC diet . 7 . BMI &lt; 36 kg/m2 . 8 . Patients must willing able comply schedule visit , treatment plan , laboratory test , study procedure . 1 . Patients myocardial infarction , stroke , transient ischemic attack , cardiovascular surgery major operation within 6 month prior screen visit . 2 . Patients percutaneous coronary intervention within 3 month . 3 . Patients take lipidlowering medication include statin XZK 4 week prior screen visit . 4 . Patients uncontrolled hypertension screen visit . Patients stable antihypertensive medication may enrol provided medication dosage remain stable throughout study . 5 . Patients take anticoagulant except aspirin &lt; 325 mg/day . 6 . Patients liver dysfunction indicate serum alanine aminotransferase ( ALT ) serum aspartate aminotransferase ( AST ) level &gt; 1.5times upper limit normal ( ULN ) range , clinical symptom . 7 . Patients elevate creatine phosphokinase level ( Upper Limit Normal range ) . 8 . Patients renal dysfunction indicate serum creatinine level ULN range , clinical symptom . 9 . Patients gastric peptic ulcer within 3 month prior screen visit . 10 . Patients uncontrolled diabetes mellitus define HbA1c level &gt; 7.0 % . 11 . Patients medical history hypothyroidism , pancreatitis , cholestasis , nephrotic syndrome , gall bladder disease , primary biliary cirrhosis . Patients thyroid replacement therapy stable dos may enrol clinically euthyroid . 12 . Patients clinically relevant illness within 4 week prior screen visit may interfere conduct study . 13 . Patients history alcohol narcotic substance abuse within two year prior screen visit . 14 . Patients hypersensitivity lipidlowering agent . 15 . Patients take another investigational drug within 4 week prior screen visit . 16 . Patients uncontrolled metabolic endocrine disease know influence lipid value . 17 . Patients know HIV positive . 18 . Patients history presence active malignancy ( nonmelanoma skin cancer ) clinically significant psychiatric , neurological , respiratory , hematological , condition opinion investigator might interfere contraindicate participation patient study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>Lipids</keyword>
	<keyword>Lipoproteins</keyword>
	<keyword>XueZhiKang</keyword>
	<keyword>Botanical</keyword>
</DOC>